1. Home
  2. UTHR vs COHR Comparison

UTHR vs COHR Comparison

Compare UTHR & COHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • COHR
  • Stock Information
  • Founded
  • UTHR 1996
  • COHR 1971
  • Country
  • UTHR United States
  • COHR United States
  • Employees
  • UTHR N/A
  • COHR N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • COHR Electronic Components
  • Sector
  • UTHR Health Care
  • COHR Technology
  • Exchange
  • UTHR Nasdaq
  • COHR Nasdaq
  • Market Cap
  • UTHR 20.7B
  • COHR 20.2B
  • IPO Year
  • UTHR 1999
  • COHR 1987
  • Fundamental
  • Price
  • UTHR $480.44
  • COHR $137.23
  • Analyst Decision
  • UTHR Buy
  • COHR Strong Buy
  • Analyst Count
  • UTHR 12
  • COHR 14
  • Target Price
  • UTHR $495.08
  • COHR $137.77
  • AVG Volume (30 Days)
  • UTHR 552.8K
  • COHR 5.0M
  • Earning Date
  • UTHR 10-29-2025
  • COHR 11-05-2025
  • Dividend Yield
  • UTHR N/A
  • COHR N/A
  • EPS Growth
  • UTHR 16.08
  • COHR N/A
  • EPS
  • UTHR 26.38
  • COHR 0.76
  • Revenue
  • UTHR $3,128,400,000.00
  • COHR $6,043,358,000.00
  • Revenue This Year
  • UTHR $13.68
  • COHR $10.48
  • Revenue Next Year
  • UTHR $5.63
  • COHR $11.20
  • P/E Ratio
  • UTHR $17.89
  • COHR $182.74
  • Revenue Growth
  • UTHR 13.50
  • COHR 20.80
  • 52 Week Low
  • UTHR $266.98
  • COHR $45.58
  • 52 Week High
  • UTHR $479.50
  • COHR $168.57
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 71.92
  • COHR 51.35
  • Support Level
  • UTHR $444.04
  • COHR $132.51
  • Resistance Level
  • UTHR $464.27
  • COHR $164.01
  • Average True Range (ATR)
  • UTHR 12.13
  • COHR 9.35
  • MACD
  • UTHR 2.39
  • COHR -1.76
  • Stochastic Oscillator
  • UTHR 98.54
  • COHR 29.29

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About COHR Coherent Corp.

Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.

Share on Social Networks: